Here's a story about what you do when the referee makes a call you don't like: you ask to speak to the manager. Outlook Therapeutics Inc. (OTLK) announced on Monday that it has done just that, submitting a formal dispute resolution request to the U.S. Food and Drug Administration over the rejection of its eye drug.
The drug in question is ONS-5010, also known as LYTENAVA, which is designed to treat neovascular age-related macular degeneration, a leading cause of vision loss. The company got a Complete Response Letter—the FDA's polite way of saying "not yet"—back in December 2025. This was actually the second such letter for this drug; the first came in August 2023.
The good news for Outlook is that the FDA has accepted the dispute request. Even better, they've granted a meeting with what's called the "deciding official" to hash things out. That meeting is set for April 2026. So, mark your calendars for a high-stakes regulatory showdown.
What's the Company's Argument?
Outlook isn't just complaining. It's bringing data to the fight. The company points to its NORSE TWO Phase 3 trial, which it says was a randomized, double-masked, active-controlled study that met its primary and key secondary endpoints. In simpler terms: in their key clinical test, the drug showed "clinically meaningful and statistically significant improvements in visual acuity."
They've also submitted additional evidence from other studies, like NORSE EIGHT, which they say further supports the drug's efficacy and safety. Crucially, they note that "the FDA has raised no safety concerns." The entire dispute seems to hinge on one thing: the FDA's conclusion that there isn't "substantial evidence of effectiveness."
The agency's latest letter, from December, stated that the extra data Outlook provided "do not alter the previous review conclusion." So, it's a classic standoff. The company says, "Look at all this positive data." The FDA is essentially replying, "We looked. It's not convincing enough for us."
Why This Drug Matters
This isn't just another drug application. In the U.S., ONS-5010 remains investigational. But if it gets the green light, it would become the first FDA-approved ophthalmic formulation of bevacizumab. Bevacizumab is a widely used cancer drug that's often repurposed off-label by eye doctors because it's cheap and effective. Getting a version specifically approved and manufactured for eye injections would be a big deal for standardizing treatment.
Outlook is also leaning into its preparedness. The product is already approved in Europe. The company is emphasizing its "robust pharmacovigilance" (fancy word for safety monitoring) and a domestic U.S. manufacturing supply chain. The message is: "We're not just asking for approval; we're ready to roll it out safely and reliably if we get it."
OTLK Price Action: In a modest show of confidence, shares of Outlook Therapeutics were up 4.64% at $0.20 at the time of publication on Tuesday. For context, the stock is trading near its 52-week low of $0.16, according to market data.
.jpeg)
